Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Glaukos Corporation Common Stock (NY:GKOS)

140.72 +2.96 (+2.15%)
Streaming Delayed Price Updated: 3:11 PM EDT, Jun 25, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Glaukos Corporation Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
News headline image
Glaukos Announces Completion of Patient Enrollment in Phase 2 Study of GLK-321 for Demodex Blepharitis
From Glaukos Corporation
Via Business Wire
GKOS (Glaukos Corp) Shows Strong Trend Template Compliance and High Growth Momentum on ChartMill ↗
Via Chartmill
News headline image
Glaukos Announces Participation in Upcoming Investor Conferences
From Glaukos Corporation
Via Business Wire
News headline image
Glaukos (GKOS) Q1 2026 Earnings Transcript ↗
Glaukos (GKOS) Q1 2026 Earnings Transcript 
Via The Motley Fool
Glaukos Corp (NYSE:GKOS) Shares Surge on Record Sales and Raised Guidance After Q1 Beat ↗
Via Chartmill
Glaukos Corp (NYSE:GKOS) Shows High-Growth Momentum and Fits Key Trend Template Rules ↗
Via Chartmill
Glaukos Corp (NYSE:GKOS) Reports Record 2025 Sales but Shares Dip on Wider Loss, Conservative Outlook ↗
Via Chartmill
News headline image
Glaukos Announces First Quarter 2026 Financial Results
From Glaukos Corporation
Via Business Wire
News headline image
Glaukos Announces the Release of its 2025 Sustainability Report
From Glaukos Corporation
Via Business Wire
News headline image
Glaukos Receives Permanent J-code for Epioxa™
From Glaukos Corporation
Via Business Wire
News headline image
Glaukos to Release First Quarter 2026 Financial Results after Market Close on April 29
From Glaukos Corporation
Via Business Wire
News headline image
Glaukos to Present Multiple Scientific Abstracts at the 2026 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting
From Glaukos Corporation
Via Business Wire
News headline image
Glaukos Announces Commercial Availability of Epioxa™, a Transformative Innovation in Interventional Keratoconus Care
From Glaukos Corporation
Via Business Wire
News headline image
Xenon Stock at $42: What to Know of a $75 Million Trim Ahead of March Phase 3 Data ↗
This biotech specializes in clinical-stage therapies for neurological disorders, with a pipeline targeting epilepsy and related conditions. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Inside a $58 Million Bet on Kodiak Amid $184 Million Offering and Phase 3 Readouts Ahead ↗
Focused on retinal disease therapies, Kodiak Sciences leads with clinical-stage candidates targeting major unmet needs in ophthalmology. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
This Fund Just Disclosed a New $55 Million Bet on Centessa Amid 53% Stock Rally and CEO Transition ↗
This UK-based biotech advances clinical-stage therapies for rare diseases, targeting specialty care markets with a diversified pipeline. 
Via The Motley Fool
News headline image
CG Oncology Soars 102% in a Year, but One Investor Just Disclosed a $58.5 Million Sale ↗
This clinical-stage biotech develops bladder-sparing therapies for high-risk cancer patients with limited treatment options. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
BrightSpring Stock Up 86% as Braidwell Takes $45 Million Stake in Healthcare Services Provider ↗
BrightSpring Health Services delivers integrated pharmacy and clinical care to Medicare, Medicaid, and insured patients nationwide. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Glaukos (GKOS) Q4 2025 Earnings Call Transcript ↗
Glaukos (GKOS) Q4 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Glaukos Announces Fourth Quarter and Full Year 2025 Financial Results
From Glaukos Corporation
Via Business Wire
News headline image
Director Sells GKOS 15,000 Shares for $1.9 Million ↗
This ophthalmic device maker, focused on glaucoma solutions, reported a notable insider sale after a challenging year for its stock. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Glaukos Announces US FDA Approval of NDA Supplement Allowing for Re-Administration of iDose® TR
From Glaukos Corporation
Via Business Wire
News headline image
Glaukos to Release Fourth Quarter and Full Year 2025 Financial Results after Market Close on February 17
From Glaukos Corporation
Via Business Wire
These stocks are moving in today's after hours session ↗
Via Chartmill
News headline image
Glaukos Announces Preliminary, Unaudited Fourth Quarter and Full Year 2025 Net Sales and Reaffirms 2026 Revenue Guidance
From Glaukos Corporation
Via Business Wire
News headline image
Glaukos Announces Participation in J.P. Morgan Healthcare Conference
From Glaukos Corporation
Via Business Wire
News headline image
Brown Capital Sells $35 Million in Glaukos Stock After Sharp Sell-Off ↗
Brown Capital Sells $35 Million in Glaukos Stock After Sharp Sell-Off 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Glaukos Announces Participation in Upcoming Investor Conferences
From Glaukos Corporation
Via Business Wire
News headline image
Why Glaukos Stock Zoomed Almost 14% Higher on Thursday ↗
The company's recent past featured robust growth, and it anticipates continued rises into the near future. 
Via The Motley Fool
News headline image
Glaukos (GKOS) Q3 2025 Earnings Call Transcript ↗
Glaukos (GKOS) Q3 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.